<DOC>
	<DOCNO>NCT02436252</DOCNO>
	<brief_summary>This phase 1/2 , uncontrolled , open-label , multicenter study patient MDS effective therapy currently exist .</brief_summary>
	<brief_title>Study DSP-7888 Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>This phase 1/2 , uncontrolled , open-label , multicenter study patient MDS effective therapy currently exist . In Phase 1 part , high risk low risk patient MDS require additional treatment enrol , two different dose level DSP-7888 ( 3.5 10.5 mg/body ) investigate stepwise manner start low dose use 3+3 design , determine MTD RD Phase 2 part base DLT evaluation 29 day follow initial dose DSP-7888 . In Phase 2 part , DSP-7888 therapy RD determine Phase 1 part administer high risk patient MDS receive responded azacitidine standard treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>[ For Phase 1 part ] Patients diagnosis MDS accord either fourth edition WHO classification FAB classification , exception chronic myelomonocytic leukemia ( CMML ) refractory anemia excess blast transformation ( RAEBt ) Patients International Prognostic Scoring System ( IPSS ) score ≧ 1.5 enrollment , patient IPSS score &lt; 1.5 require additional treatment supportive therapy opinion investigator subinvestigator . Patients able hospitalized initial dose DSP7888 end postinitial dose observation ( Patients may permit temporary overnight leave hospitalization . ) [ For Phase 2 part ] Patients diagnosis MDS accord either fourth edition WHO classification FAB classification Patients IPSS score ≧ 1.5 enrollment , patient IPSS score &lt; 1.5 myeloblast ≧ 5 % Patients receive least one cycle azacitidine therapy [ For Phase 1 2 part ] Patients peripheral white blood cell count ≦12,000/mm3 within 4 week ( 28 day ) enrollment ( basis recent data period multiple data available ) Patients age ≧20 year time informed consent Patients provide write voluntary consent person participate study fully receive understand information study , include study objective , content , expect pharmacological action effect , foreseeable risk Patients Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) score 0 2 enrollment Patients life expectancy ≧ 3 month ( 90 day ) Patients standard therapy currently available , include transplant treatment allogeneic stem cell transplant Patients human leukocyte antigen ( HLA ) type HLAA*24:02 HLAA*02:01/06 Patients adequate major organ function meet follow criterion basis laboratory data within 4 week ( 28 day ) enrollment ( multiple data available , recent data period ) Serum creatinine : ≦ 2fold upper limit normal range study site ( ULN ) Total bilirubin : ≦2fold ULN AST , ALT : ≦3fold ULN Female patient childbearing potential male patient female partner childbearing potential must agree use appropriate contraception time consent 6 month ( 180 day ) last dose study drug avoid pregnancy Female patient childbearing potential must negative pregnancy test ( urine ) within 4 week ( 28 day ) enrollment Patients dry tap bone marrow aspiration enrollment Patients grade ≧ 3 infection accord Common Terminology Criteria Adverse Events , version 4.0 ( CTCAE v4.0 ) Patients positive test result HIV antibody , HBs antigen HCV antibody Patients intracranial metastasis symptomatic require treatment Patients active multiple cancer ( synchronous multiple cancer , metachronous multiple cancer diseasefree period ≦ 5 year , exception carcinoma situ , mucosal carcinoma , carcinomas curatively treated local therapy ) Patients myocardial infarction within 6 month ( 180 day ) enrollment Patients significant disease enrollment may affect study treatment , New York Heart Association ( NYHA ) Functional Class III IV heart disease , CTCAE v4.0 grade ≧ 3 arrhythmia , angina pectoris , abnormal electrocardiogram finding , interstitial pneumonia pulmonary fibrosis Patients uncontrollable complication Patients CTCAE v4.0 grade ≧2 hemorrhage Patients underwent allogeneic hematopoietic stem cell transplant Patients receive following treatment within specified period enrollment : Surgery , radiotherapy , chemotherapy ( include moleculartargeted drug ) : 4 week ( 28 day ) Immunosuppressants , cytokine preparation ( exclude GCSF ) : 4 week ( 28 day ) Endocrine therapy , immunotherapy ( include biological response modifier therapy ) : 2 week ( 14 day ) Pregnant woman breastfeed woman Patients concurrent autoimmune disease history chronic recurrent autoimmune disease , patient require longterm systemic steroid therapy ( exclude therapy give PRN basis ) Patients ongoing CTCAE v4.0 grade ≧ 2 adverse effect prior treatment ( exclude alopecia phlebitis ) Patients receive investigational product postmarketing study drug within 4 week ( 28 day ) enrollment Patients history allergy oily drug product Patients previously receive DSP7888 , WT1 peptide , WT1 immunotherapy Patients inappropriate participation study reason opinion investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>